Here was a significant inhibition of enzyme
activity T after administration FTase tipifarnib in all patients. The effect of tipifarnib on GGTase I enzyme activity T variable, is also decreased in six patients, increased in two patients, ENMD-2076 and Invariant changed in three patients. With respect to the effects on the expression of signaling proteins Tipifarnib there were significant inhibition of the STAT p was observed in seven out of nine evaluable patients, but it was different effects on S. ERK, AKT and the expression p p. Repr Sentative results from two patients are shown in the figure, including normal a patient. PCR and a second patient who had a post-treatment score of RCB In summary, although the tumor FT ase enzyme activity T was significantly reduced by tipifarnib in most patients and p STAT reduced in most Cases there is no correlation between the inhibition of the enzyme FT ase or STAT inhibition and breast pCR p.
Pr Diktiver biomarker data analysis of biomarkers for tumor sample pretreatment was for patients with inflammatory carcinoma of the breast and had a pCR. The median value for each marker in percent positive tumor cells are expressed in the table shown. for Ki, p STAT, ERK p, p, and p, the median score markers Rheb and AKT are expressed also shown. There was no relationship between a marker and is sensitive to the therapy or treatment of resistance, with the exception of Ki, Ki was significantly low score with treatment resistance. Rho A, B and C, the percentage of samples which have been classified, and are shown in the figure.
There was no significant correlation between the expression of RhoA, B and C with the protein either reaction or Best Resistance to over treatment. There was no association between Rho A, B, C, and expression of inflammatory Ph Genotype. Three evaluable F lle With inflammatory diseases were RhoC against four F Cases not evaluated inflammatory. Information on the overall treatment tipifarnib combination AC cycles were given. F??nfunddrei moderately patients U four cycles of the combination. Nine patients were U at least four cycles of AC tipifarnib combination, including three patients U cycle four who U two cycles and two who U three cycles again again again. The reasons for the judgment of the tipifarnib including normal gastrointestinal side effects such as nausea, vomiting and Verdauungsst Requirements or five patient preferences Pr Patient in two patients, neutropenia and thrombocytopenia in one patient and persistent Todesf Lle pneumonia in a patient.
CA dose was t in four patients due to toxicity, Including normal febrile neutropenia, thrombocytopenia and on Reduced premium. Second cycles, or after the treatment administered to patients Where U at least two cycles of treatment with alternating Tipifarnib have again, all of the cycles have been given in the time patients. Zw Galv lf treatment cycles Siege were a week or l singer in ten patients because of side effects, including three patients with infections of the skin quality t and patients registered with chest pain each year Ing hospitalization, grade ? Thrombocytopenia, stomatitis, the predicate On Anemia, febrile neutropenia and persistent sinus tachycardia. The worst toxicity t Degree of toxicity T is observed in RPTD shown in the table. Neutropenia and leukopen